IPA - immunoprecise.com Future Price to Earnings
ImmunoPrecise Antibodies (IPA) is a recognized leader in AI-driven targeted antibody development trusted by the largest pharmaceutical behemoths. The company's forward P/E clearly captures market expectations, while the 47.10 metric confirms the current valuation level. This Canadian biotech is shielded from geopolitical risks by its medical status. An impeccable image as an innovative "discovery factory" is accelerating the global search for new drugs.
Summary analytical data breakdowns for ImmunoPrecise (IPA)
- stock value and consensus price forecast:
- market capitalization statistics:
- balance sheet equity data:
- debt level and financial liquidity data:
Total Debt to Capital ImmunoPrecise Antibodies|IPA - Long-Term Liabilities to Capital|Short-Term Debt to Capital ImmunoPrecise Antibodies|IPA - Company Total Debt|Debts to Book Capitalization ImmunoPrecise Antibodies Ltd|IPA - Long-Term Debt Volume|Company Short-Term Debt ImmunoPrecise Antibodies|Quick Ratio immunoprecise.com
- company profitability and valuation multiples indicators:
IPA - Company Net Income|Future Profit ImmunoPrecise Antibodies|IPA - Company Value to Net Income|Forward P/E Multiple ImmunoPrecise Antibodies|IPA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ImmunoPrecise Antibodies Ltd|IPA - Operating profit before amortization|Net earnings per share for the last 12 months ImmunoPrecise Antibodies|IPA - Earnings per share for the last four quarters|Quarterly EPS earnings growth immunoprecise.com|IPA - Expected net earnings per share growth this year|Earnings growth forecast for next year ImmunoPrecise Antibodies
Fundamental company analysis:ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies (IPA) optimizes antibody discovery via AI platforms, reducing chemical waste and adhering to ESG ethical standards. By analyzing the company's projected P/E multiple valuation, an investor assesses the current share price relative to expected net income; however, ignoring the macroeconomic backdrop and relying solely on historical multiple peaks during a liquidity crunch could lead to substantial capital loss.
Main competitors
Future Price to Earnings Tempus Labs (TEM)|Qiagen NV - Price to Future Earnings Ratio|Future Price to Earnings Ionis Pharma IONS|Repligen Inc. (RGEN) - Projected Price to Earnings Ratio|RNA - Future Price to Earnings|Price to Expected Earnings Ratio CRSP|GeneDx (WGS) - Future Price to Earnings|Ultragenyx Pharmaceutical Inc. - Future Price to Earnings Multiple|BEAM (Beam Therapeutics Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Sarepta Corp SRPT|Forward P/E Multiple TWST|Projected Price to Earnings 10xgenomics.com TXG|Forward P/E Multiple NTLA (Intellia Therapeutics, Inc.)|Market Cap to Projected Earnings Stoke Therapeutics Inc (STOK)|BLFS - Future Price to Earnings|Market Cap to Projected Earnings Wave Pharma WVE|MAZE: Forward P/E Multiple|Projected Price to Earnings Ratio sionnatx.com (SION)|Projected Price to Earnings PRME|TSHA: Future Price to Earnings Multiple|Forward P/E Multiple QURE|Forward P/E Multiple MeiraGTx Corp (MGTX)|Future Price to Earnings REGENXBIO Inc. RGNX|SLDB: Price to Future Earnings Ratio|OCGN: Projected Price to Earnings|Pacific Biosciences of California, Inc. - Market Cap to Future Earnings Ratio|BNTC: Forward P/E Multiple|DSGN - Market Cap to Projected Earnings|RCKT (Rocket Pharmaceuticals) - Forward P/E Multiple|Future Price to Earnings FDMT|Future Price to Earnings Lexeo Therapeutics (LXEO)|KRRO - Projected Price to Earnings Ratio|Forward P/E Multiple EDIT (Editas)|SLN: Price to Future Earnings Ratio|ProQR Therapeutics NV - Forward P/E Multiple|Market Cap to Projected Earnings Codexis, Inc. CDXS|SGMO: Forward P/E Multiple|Projected Price to Earnings Ratio Nautilus Bio (NAUT)|Future Price to Earnings Metagenomi, Inc|Precision BioSciences Inc. (DTIL) - Market Cap to Projected Earnings|Forward P/E Multiple GBIO|Market Cap to Projected Earnings boundlessbio.com|Future Price to Earnings Exicure XCUR|IMNN (Imunon Inc) - Price to Expected Earnings Ratio|RXi Pharmaceuticals - Forward P/E Multiple|MBIO - Forward P/E Multiple|RNAZ: Forward P/E Multiple|Price to Future Earnings Ratio BNGO|Future Price to Earnings Applied DNA Sciences, Inc.|Price to Future Earnings Ratio BLUE (bluebird bio Inc.)|Forward P/E Multiple OMGA|Forward P/E Multiple Singular Genomics Corp (OMIC)|Forward P/E Multiple RGLS (Regulus Therapeutics)|Market Cap to Projected Earnings syros.com (SYRS)|TBIO - Future Price to Earnings|TRACON Pharmaceuticals Inc. (TCON) - Projected Price to Earnings|Unity Bio (UBX) - Future Price to Earnings
